Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing first- or best-in-class medicines against well characterized biology and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. The company has six investigational medicines in clinical studies, including new combination approaches that target TIGIT, PD-1, the adenosine axis (CD73 and dual A2a/A2b) and most recently, HIF-2a. For more information about its clinical and pre-clinical programs, please visit www.arcusbio.com or follow us on Twitter.
Additional Info
Will your company display a new product or promote a new indication/enhanced feature(s) for an existing product in your booth?
No